← Leaderboards
Esteban Edward Mena
Lifepharms, Inc.
$9,274,176
Attributed
$9,274,176
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,274,176 · 11
By mechanism
U01$4,374,177 · 1
R43$2,477,465 · 8
R44$2,422,534 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsLeadInfectionIn VitroInhibitor/AntagonistAnalogBiological FactorsLibrariesAscomycotaToxic EffectBasidiomycotaScreening ProcedureAgaricalesDrug ResistanceResearch StudyMammalian CellSourcePathogenDrug DiscoveryResistanceSamplingIn VivoCellsStructure
Grant awards (18)
The development of a novel antifungal for drug resistance$300,000
R43 · FY2025 · AI · contact PI
Antifungal therapy against drug resistant fungal pathogens.$743,940
R44 · FY2016 · AI · contact PI
Antifungal therapy against drug resistant fungal pathogens.$774,112
R44 · FY2015 · AI · contact PI
Hsp90 inhibitors to combat antifungal drug resistance.$299,998
R43 · FY2012 · AI · contact PI
Novel Antibacterial Scaffold from Natural Products$287,757
R43 · FY2012 · AI · contact PI
Novel Antibacterial Scaffold from Natural Products$300,000
R43 · FY2011 · AI · contact PI
Novel antifungals for Immunocompromised/HIV patients.$300,000
R43 · FY2011 · AI · contact PI
Discovery of novel agents against M. tuberculosis.$300,000
R43 · FY2010 · AI · contact PI
Nucleoside hydrolase Inhibitors from natural products for Leishmania$211,698
R43 · FY2010 · AI · contact PI
Inhibitors of poxvirus enzymes as novel drugs$896,022
U01 · FY2009 · AI · contact PI
Discovery of novel antibacterials from a mushroom natural product library$378,012
R43 · FY2009 · AI · contact PI
Inhibitors of poxvirus enzymes as novel drugs$870,266
U01 · FY2008 · AI · contact PI
Inhibitors of poxvirus enzymes as novel drugs$861,830
U01 · FY2007 · AI · contact PI
Inhibitors of poxvirus enzymes as novel drugs$839,005
U01 · FY2006 · AI · contact PI
Discovery of cell cycle inhibitors from natural products$439,536
R44 · FY2006 · CA · contact PI
Inhibitors of poxvirus enzymes as novel drugs$907,054
U01 · FY2005 · AI
Discovery of cell cycle inhibitors from natural products$464,946
R44 · FY2005 · CA
POTENTIAL ANTICANCER AGENTS FROM BASIDIOMYCETES$100,000
R43 · FY2001 · CA